1.
Alberg DG, Schreiber SL. Structure-based design of a cyclophilin-calcineurin bridging ligand. Science. 1993;262(5131):248-50.
1.
Nishimasu H, Yamano T, Gao L, Zhang F, Ishitani R, Nureki O. Structural Basis for the Altered PAM Recognition by Engineered CRISPR-Cpf1. Mol Cell. 2017;67(1):139-147.e2. doi:10.1016/j.molcel.2017.04.019.
1.
Awad MM, Liu S, Rybkin II, et al. Acquired Resistance to KRAS Inhibition in Cancer. N Engl J Med. 2021;384(25):2382-2393. doi:10.1056/NEJMoa2105281.
1.
Yu H, Rosen MK, Shin TB, Seidel-Dugan C, Brugge JS, Schreiber SL. Solution structure of the SH3 domain of Src and identification of its ligand-binding site. Science. 1992;258(5088):1665-8.
1.
Yamano T, Zetsche B, Ishitani R, Zhang F, Nishimasu H, Nureki O. Structural Basis for the Canonical and Non-canonical PAM Recognition by CRISPR-Cpf1. Mol Cell. 2017;67(4):633-645.e3. doi:10.1016/j.molcel.2017.06.035.
1.
Necci M, Piovesan D, CAID Predictors, DisProt Curators, Tosatto SCE. Critical assessment of protein intrinsic disorder prediction. Nat Methods. 2021;18(5):472-481. doi:10.1038/s41592-021-01117-3.
1.
Georghiou G, Kleiner RE, Pulkoski-Gross M, Liu DR, Seeliger MA. Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles. Nat Chem Biol. 2012;8(4):366-74. doi:10.1038/nchembio.792.
1.
Karanicolas J, Corn JE, Chen I, et al. A de novo protein binding pair by computational design and directed evolution. Mol Cell. 2011;42(2):250-60. doi:10.1016/j.molcel.2011.03.010.
1.
Lieberman-Aiden E, van Berkum NL, Williams L, et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science. 2009;326(5950):289-93. doi:10.1126/science.1181369.
1.
Buskirk AR, Liu DR. Creating small-molecule-dependent switches to modulate biological functions. Chem Biol. 2005;12(2):151-61. doi:10.1016/j.chembiol.2004.11.012.